| P2093 | author name string | E Reed | |
| | J Hawthorn | |
| | I Kössler | |
| P2860 | cites work | Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. | Q30923126 |
| | Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study | Q31960153 |
| | Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group | Q33328841 |
| | Clinical interpretation of quality-of-life outcomes: an investigation of data from the randomized trial of gemcitabine plus paclitaxel compared with paclitaxel alone for advanced breast cancer | Q33330459 |
| | Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer | Q33330619 |
| | Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer | Q33488625 |
| | Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer | Q33834401 |
| | Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer | Q33905833 |
| | Are quality of life measures patient centred? | Q34270312 |
| | Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate | Q34516345 |
| | Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results | Q34524041 |
| | Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. | Q34818002 |
| | Quality of life in patients undergoing systemic therapy for advanced breast cancer | Q34953360 |
| | Health-related quality-of-life measurement in randomized clinical trials in breast cancer--taking stock | Q35068200 |
| | Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial | Q35584284 |
| | Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer | Q35666117 |
| | Quality of life in randomized trials of cytotoxic or hormonal treatment of advanced breast cancer. Is there added value? | Q35940718 |
| | Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer | Q36024588 |
| | Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study | Q36285977 |
| | Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast. | Q36619598 |
| | Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer. | Q36957686 |
| | What are quality of life measurements measuring? | Q37150585 |
| | The problem of quality of life in medicine | Q39227551 |
| | Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. | Q40606333 |
| | Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter? | Q40789907 |
| | Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group | Q42550309 |
| | Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer | Q42653377 |
| | Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. | Q42882393 |
| | Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine) | Q42948576 |
| | Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist | Q43644874 |
| | Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial | Q44026235 |
| | Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial | Q44102213 |
| | Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment | Q44102217 |
| | Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. | Q44362096 |
| | Daily assessment of stressful events and coping among post-menopausal women with breast cancer treated with adjuvant chemotherapy | Q44567786 |
| | Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epir | Q44598300 |
| | Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial | Q44875574 |
| | Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. | Q45014464 |
| | Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group | Q45059044 |
| | Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. | Q45086545 |
| | Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial | Q45130067 |
| | Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment | Q46157015 |
| | Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. | Q46720989 |
| | Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin | Q48716555 |
| | Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group | Q48717671 |
| | Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. | Q49273085 |
| | A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. | Q53136703 |
| | Quality of life in metastatic breast cancer patients under chemotherapy or supportive care: a single-institution comparative study. | Q53178812 |
| | A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study. | Q53185474 |
| | Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19. | Q53236983 |
| | Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). | Q53396920 |
| | Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. | Q53426459 |
| | Understanding self-rated health. | Q53455342 |
| | Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. | Q53519477 |
| | Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. | Q53525799 |
| | Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Essen Breast Cancer Study Group. | Q53542638 |
| | Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer | Q53637895 |
| | Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. | Q54071888 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 565-580 | |
| P577 | publication date | 2012-06-04 | |
| P1433 | published in | European Journal of Cancer Care | Q5412710 |
| P1476 | title | Quality of life assessments in advanced breast cancer: should there be more consistency? | |
| P478 | volume | 21 | |